BELANO Medical - The Micro­biotics Company


Alexander Welsch to Become New Head of Sales at BELANO medical AG

Global marketing of micro­biome products expanded
Hennigsdorf b. Berlin, 26 May 2021 – BELANO medical AG will expand its health care activities as well as European and global sales and marketing of micro­biome-based products. Therefore, the super­visory board decided to expand the company’s management board by a position for marketing and sales, and appointed Alexander Welsch to the board to handle this new respon­si­bility. Currently, the 48-year-old is chief executive at SIRIUS GmbH für kosme­tische und pharma­zeu­tische Produkte, a Dr. KADE Health Care company. He will start his new position on 1 June.

“Alexander Welsch contri­buted to the successful launching of familiar brands such as Anti-Brumm, Lefax, and DOC pain relief gel where he showcased his expertise, experience, and creativity”, explains Renke Lührs, Chairman of BELANO medical AG’s super­visory board. He was well-respected in the industry, a result of more than 20 years of executive experience in sales and marketing positions for NEM, OTC, and derma­to­lo­gical cosmetics, as well as the signi­ficant sales increases achieved for widely-known brand-name products. “We rely on his widely-ranging experience and his network to market our medical skincare and other micro­biome products globally and to continue building the BELANO medical brand”, Lührs continues.

Alexander Welsch began his career at Bayer Vital Consumer Care GmbH before moving into marketing at Klosterfrau GmbH in Cologne. As head of marketing, he went to Hermes Arznei­mittel GmbH and later became chief executive at Dr. B. Scheffler GmbH, head of pharmaceu­tical marketing and sales at Krüger GmbH, as well as chief executive of Vendus Business Partner GmbH.
BELANO medical AG holds a number of patents on micro­biotic (microbial) agents which are used in its own medical skincare products as well as in private label health care products of partners such as Henkel AG and the Müller chain of retail stores. By issuing a conver­tible bond (WKN: A3H2UW; ISIN: DE000A3H2UW2) at the end of last year, BELANO medical estab­lished the financial basis for further building its business.

About BELANO medical AG:
BELANO medical AG is a biotech­nology company which leverages the findings of its research into beneficial micro­or­ga­nisms for pharmaceu­tical and care products. The company develops and brings to market novel approaches to medical skin care, disease prevention, and the support of healing processes with the aim of creating new thera­peutic options for diseases and indica­tions which currently cannot be treated satis­fac­torily. BELANO’s mission is to make its patented agents and products available to everyone. To do so, the company relies on national and inter­na­tional colla­bo­ra­tions with distri­butors and larger partners such as Henkel AG or the Müller chain of retail stores.

Scroll to Top